RA0643

antibody from Oursmab

Targeting: SAA1 PIG4, SAA, TP53I4

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0643

Provider

Oursmab

Product name

Birtamimab (Biosimilar Reference Antibody) (SAA1)

Antibody type

Monoclonal

Description

Birtamimab is a humanized monoclonal antibody designed to target and clear misfolded forms of serum amyloid A (SAA) protein, specifically amyloid fibrils and oligomers. It is developed for the treatment of light-chain (AL) amyloidosis, a rare and often fatal disease where misfolded immunoglobulin light chains form amyloid deposits that damage organs (particularly the heart). Birtamimab binds to a cryptic epitope exposed on misfolded SAA-related amyloid, marking it for clearance by phagocytic immune cells (e.g., macrophages). Despite promising Phase I/II data, a pivotal Phase III trial in patients with newly diagnosed AL amyloidosis and cardiac involvement did not meet its primary endpoint. However, a pre-specified subgroup analysis suggested potential benefit in a very high-risk patient population, leading to further investigation.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.